Related Experiment Video
Updated: Jul 12, 2026

Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
Targeting DNA Methylation: New Paradigms and the Advent of Gene-Selective Tools
Julie Gilbert1, Francesco Calzaferri2
1University of Oxford, Department of Chemistry, 12 Mansfield Road, OxfordOX1 3TA, U.K.
Abstract:
DNA methylation can function as a toxic alkylation reaction exploited by chemotherapeutic agents to induce cancer cell death. However, finely tuned DNA methylation plays a fundamental role in cellular physiology, particularly in the epigenetic regulation of gene expression. Once thought to act solely as a repressor of gene transcription, its functional role has since been elucidated as genomic locus-specific and deeply connected with other epigenetic factors. Following the clinical approval of DNA methyltransferase inhibitors, such as Azacitidine and Decitabine, for the treatment of hematological malignancies, considerable efforts have been devoted to developing pharmacological tools that modulate epigenetic DNA methylation. However, the lack of gene selectivity in these agents limits their therapeutic efficacy and increases off-target toxicity. Moreover, the non-gene-selective nature of current DNA methylation-targeting molecules fails to meet the standards required to discern the nuanced roles of DNA methylation across diverse pathophysiological contexts and genomic loci, particularly in an era where next-generation sequencing and omics technologies enable high-resolution epigenetic analyses. In this review, we examine the mechanisms and roles of DNA methylation in epigenetic regulation, evaluate the current landscape of DNA methylation modulators, from traditional DNMT inhibitors to cutting-edge CRISPR-dCas9 fusion systems and protein-protein interaction disruptors, and discuss their clinical relevance. Finally, we emphasize the need for precise, locus-specific tools to advance both cancer research and therapeutic strategies.
Insights
DNA methylation is crucial for gene regulation. Current drugs lack specificity, highlighting the need for precise, locus-specific epigenetic tools for cancer research and therapy.
Area of Science:
- Epigenetics and Molecular Biology
- Cancer Therapeutics
Background:
- DNA methylation is vital for cellular physiology and epigenetic gene regulation.
- While DNA methyltransferase inhibitors are approved for hematological malignancies, their lack of gene selectivity causes toxicity and limits efficacy.
- Next-generation sequencing and omics technologies allow high-resolution epigenetic analysis, demanding more precise tools.
Purpose of the Study:
- To review the mechanisms and roles of DNA methylation in epigenetic regulation.
- To evaluate current DNA methylation modulators, including DNMT inhibitors and novel CRISPR-dCas9 systems.
- To discuss the clinical relevance of these modulators and emphasize the need for locus-specific tools.
Main Methods:
- Literature review of DNA methylation mechanisms and epigenetic regulation.
- Analysis of existing pharmacological tools targeting DNA methylation, from DNMT inhibitors to advanced CRISPR-dCas9 fusion systems.
- Discussion of clinical applications and future directions in epigenetic therapy.
Main Results:
- DNA methylation's role extends beyond gene repression, being locus-specific and interacting with other epigenetic factors.
- Current non-gene-selective DNA methylation modulators exhibit limited therapeutic efficacy and off-target toxicity.
- Emerging technologies like CRISPR-dCas9 fusion systems offer potential for precise epigenetic modulation.
Conclusions:
- Precise, locus-specific tools are essential to overcome the limitations of current DNA methylation modulators.
- Advancements in epigenetic research and cancer therapy depend on developing targeted approaches.
- Future strategies must focus on gene selectivity for improved therapeutic outcomes and reduced toxicity.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Pharmacogenomics: Identification of New Drug Targets
In-vitro Mutagenesis

